The US Healthcare sector reached a new milestone

GW Pharmaceuticals, a biopharmaceutical leader in the development of cannabinoid-based medicines headquartered in Cambridge, United Kingdom, finally received the approval of the United States Food and Drug Administration (FDA) for one of its drug, Epidiolex. Designed to help fighting against epilepsy and tested with over 2’000 patients since its development in pre-clinical research in 2007, Epidiolex, the first cannabis-derived medicine accessible in the US, is expected to be available for patients under the age of 6 years with severe forms of Lennox-Gastaut and Dravet epilepsy syndromes as early as Fall 2018. Similar procedures are under review by the European Medicines Agency and awaited for the first quarter of 2019. Aside from Epidiolex, GW-Pharmaceuticals is currently waiting for the review of its multiple sclerosis treatment, Sativex, which is in phase 3 testing by the FDA and already commercialized in 30 different countries worldwide.

As GW Pharmaceuticals Chief Executive Officer Justin Gover mentions: “That underlies the whole value of this. We now remove ourselves from being a special case and now meet the standard criteria for prescription medications”, the unique selling proposition offered by the cannabis industry is increasing, and the healthcare sector finally recognizes the broader medicinal range of cannabis as a legitimate medicinal remedy.

Accordingly, growth potential of the cannabis industry continues to remain attractive as the achievement ok key milestones are boosting the industry and strengthening investment opportunities in the long-run. Due to recent decline after yesterday’s Trump announcement of another round of trade restrictions against Chinese investments in tech companies, we would highly recommend investors to benefit from current timing and build up their position by investing into SQ Cannabis Portfolio (symbol: WEEDTQ).